Document is current
Any future updates will be listed below
-
Authors
Vidal-Oliver, Lourdes
Herzig-de Almeida, Elisa
Spissinger, Sabrina
Finger, Robert P
-
Funding
Funding for this research was provided by:
Medizinische Fakultät Mannheim der Universität Heidelberg
- License Information
-
More Information
Article History
Received: 30 September 2024
Accepted: 16 November 2024
First Online: 26 November 2024
Declarations
:
: This study was performed in accordance with the tenets of the Declaration of Helsinki and was approved by the Institutional Review Board of the Medical Faculty of Mannheim (ID number: 2023 − 666). All patients provided written informed consent to participate in this study.
: Not applicable.
: LVO: Bayer (travel expenses). SS, EHA: None. RPF: Biogen, Bayer (Research money); Apellis, Alimera, Allergan, Astellas, Caterna, Bayer, Böringer-Ingelheim, Novartis, Ophthea, ODOS, ProGenerika, Roche/Genentech, Stada Pharm (Honorary or other (financial) compensation).
: None of the reported conflicts of interest relate to the content of this publication.
